Faysal Kalmoua brings over 26 years of experience in pharmaceutical drug development and commercialization, including 21 years in portfolio management, R&D, and business development. He specializes in generics and biosimilars, with deep expertise in product portfolio strategy, IP assessments and R&D.


Faysal Kalmoua has served as COO since August 2023, and as Head of Portfolio and Project Management for Alvotech since 2022 and as one of Alvotech directors since 2020. Since 2015, he has served as Executive Vice President of Portfolio, Business Development and Research and Development for Alvogen. Prior to joining Alvogen, Mr. Kalmoua served in various management positions for Synthon for nearly 16 years. Mr. Kalmoua holds a Master’s degree in Chemistry from the Radboud University Nijmegen and an executive MBA from Insead.